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Abstract Human papillomaviruses (HPV) infection in
benign laryngeal papillomas is well established. The vast
majority of recurrent respiratory papillomatosis lesions are
due to HPV types 6 and 11. Human papillomaviruses are
small non-enveloped viruses (>8 kb), that replicate within the
nuclei of infected host cells. Infected host basal cell keratino-
cytes and papillomas arise from the disordered proliferation of
these diVerentiating keratinocytes. Surgical debulking of pap-
illomas is currently the treatment of choice; newer surgical
approaches utilizing microdebriders are replacing laser abla-
tion. Surgery aims to secure an adequate airway and improve
and maintain an acceptable quality of voice. Adjuvant treat-
ments currently used include cidofovir, indole-3-carbinol,
ribavirin, mumps vaccine, and photodynamic therapy. The
recent licensing of prophylactic HPV vaccines is a most inter-
esting development. The low incidence of RRP does pose sig-
niWcant problems in recruitment of suYcient numbers to show
statistical signiWcance. Large multi-centre collaborative clini-
cal trials are therefore required. Even so, suYcient clinical fol-
low-up data would take several years.
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Introduction
Sir Morrell Mackenzie (1837–1892) was the Wrst to recog-
nize papillomas as a lesion of the laryngo-pharyngeal sys-
tem in children in the late 1800s. It is now apparent that
these benign tumours may occur at other parts of the upper
gastrointestinal and respiratory tracts, and in all age groups.
It was not until the 1940s that Chevalier Jackson (1865–
1958) Wrst coined the term “juvenile laryngeal papillomato-
sis”. The prevalence of laryngeal papillomatosis has been
estimated at between four to seven cases per million per-
son-years in the Western World [4, 5, 25, 43]. Furthermore,
the incidence of recurrent respiratory papillomatosis (RRP)
has been estimated at about 2 per 100,000 in adults and 4
per 100,000 in children [9]. The disease can be categorized
into adult onset and juvenile onset forms. Age of Wrst pre-
sentation of disease is usually in the teens (50%) for the
juvenile onset form but can be as early as the Wrst year of
life. Initial presentation in the adult form tends to peak in
the third and fourth decades.
It is now well established that human papillomaviruses
(HPVs) are the aetiological agent of many benign and
malignant tumours arising from epidermal tissues. They
are a necessary cause of the second most common female
cancer worldwide, cancer of the cervix [7,  45], and
strongly associated with several other ano-genital cancers
such anal, penile, vulval and vaginal carcinomas [17]. Fur-
thermore, there is mounting evidence of at least some head
and neck cancers associated with HPV infection [15, 17,
23]. These malignancies are associated with »15 high risk
(HR) types, in particular HPV 16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, 59, 68, 73 and 82. Benign tumours such as
common warts, Xat warts and genital warts are caused by
low risk types such as HPV 1, 2, 3, 4, 6, 10, 11 and others.
HPV 6 and 11 have been described as the dominant types
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found in RRP [10]. Despite the benign nature of these
lesions, there is signiWcant morbidity and occasional mor-
tality due to multiple recurrences which necessitate hospi-
tal admission for surgical removal. Dissemination or
extension of the growths into the lower airways indicates a
poorer prognosis. The clinical behaviour is variable and
lesions can regress, persist and in rare instances, progress
to carcinoma if other environmental factors such as smok-
ing or irradiation are involved.
Epidemiology
Human papillomaviruses infection in benign laryngeal pap-
illomas is well established. One Danish study showed that
95% of solitary laryngeal papillomas were positive for
HPV DNA by in situ hybridization [26]. Another study
from Hong Kong found that 59% of laryngeal papillomas
showed the presence of HPV 6, 11, 16, 18 subtypes, with 6
and 11 the dominant types [10]. Malignant transformation
of some lesions has been described in association with HPV
11 integration into the genome and mutation of p53 [32].
Infection with HPV 11 is more likely to be associated with
the development of distal airways disease than HPV 6.
Clinical manifestation of disease prior to three years of age
is a further risk factor associated with distal spread of dis-
ease [1, 47].
The vast majority of RRP lesions are due to HPV types 6
and 11, and the reservoir for these types is the human ano-
genital tract. Ano-genital HPV is the commonest sexually
transmitted viral infection and the prevalence of clinically
apparent genital warts is thought to be the “tip of the ice-
berg” of HPV infection. Koutsky et al. estimates that »10–
20% of the US population between 15 and 49 years of age
have molecular evidence of infection and that another 60%
have had prior infection [22]. In the UK, there were well
over 81,000 incident genital wart infections reported from
genitourinary medicine clinics in 2005 [16] and this has
been increasing every year. Such high background preva-
lence suggests that there is a risk of mother to child trans-
mission at the time of delivery, especially if there are
noticeable genital warts. Data supporting this hypothesis
showed that a history of maternal condylomata during preg-
nancy was associated with a 200-fold risk of RRP in the
child [37]. An uncomplicated vaginal delivery in a mother
with HPV infection has been estimated to carry a risk of
transmission of 1:80–1:1,500 (median of 1:400) [34]. In
one group of children with juvenile laryngeal papillomato-
sis, 54% had a maternal history of vulval condylomata at
the time of delivery [13]. Another study found that in 77
mothers with condylomata at delivery, 9 children (11.6%)
were later diagnosed with juvenile laryngeal papillomatosis
[21].
The route of transmission is likely to be diVerent in the
juvenile onset and adult onset forms of RRP. Evidence for
this has been suggested by a case control study, in which
the risk factors for both forms were compared [20]. The
authors found that adult onset patients were more likely to
have had more sexual partners and oral sex than their con-
trols. Patients with the juvenile form were more likely to
have been born to teenage mothers and Wrst-born children
compared to their controls.
Aetiological and histopathological features
Papillomatous lesions preferentially occur anatomically at
the sites of “transformation zones”, where squamous epi-
thelia abut ciliated columnar epithelia but can infect any-
where in the respiratory tract [28]. The classical sites for
recurrent disease in the upper aero-digestive tract would be
the nasopharyngeal area of the soft palate, limen vestibuli,
midzone of laryngeal area of the epiglottis, upper and lower
margins of the ventricle, vocal fold undersurface, carina
and bronchial spurs. It is interesting to note that papillo-
mata have been observed at tracheotomy sites and tracts
where the iatrogenic induction of change of epithelializa-
tion also occurs [19].
Human papillomaviruses are small nonenveloped
viruses (»8 kb), with a double stranded circular DNA
genome encapsulated within an icosahedral capsid that rep-
licate within the nuclei of infected host cells. The genome
codes for 8–10 genes (median of eight). The late L1 and L2
genes code for the viral capsid proteins, the early proteins
E1 and E2 are responsible for viral replication and tran-
scription, and E4 appears to aid virus release from infected
cells. The early genes E6 and E7 have transforming ability
in in vitro assays for HR types but LR types have little to no
ability for this feature [2, 33, 42].
Electron microscopic analysis reveals the virion to be
»55 nm in diameter and the capsid to be comprised of 72
pentameric capsomers. The predominant protein in the cap-
sid consists of the L1 protein, with a smaller proportion of
L2 embedded deep within the protein shell. It is this L1
protein which provides the dominant antigenic epitopes
recognized by neutralizing antibodies and forms the basis
for the bivalent (GlaxoSmithKline) and quadrivalent
(Merck, Hohenbrumn, Germany) vaccines currently avail-
able.
The virus is thought to bind to and gain entry to its host
cell, the basal keratinocyte, by microtrauma or abrasions to
the surface epithelium. The receptor has not been deWni-
tively identiWed but 6-integrin and heparin sulphate may
play important roles in viral entry [11, 18, 30].
Following infection and uncoating, the virus is thought
to maintain its genome as a low copy number episome inEur Arch Otorhinolaryngol (2008) 265:147–151 149
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the basal cells. It has been suggested that expression of E1
and possibly E2, may be suYcient for basal maintenance of
viral episomes [50]. Viral early proteins E6, E7, E1 and E2
are expressed at low level in early passage cell lines derived
from naturally occurring low-grade cervical lesions and the
viral genome is maintained at around 10–200 copies per
cell [8, 41].
The viral genome is ampliWed in diVerentiating keratino-
cytes via rolling-circle ampliWcation that will synthesize
suYcient viral genome for packaging [3, 12]. This require-
ment for diVerentiating epithelial cells is a key part of the
virus life cycle but the normal restraint on cell cycle pro-
gression appears to be abolished by the E6 and E7 proteins
and normal terminal diVerentiation is retarded [36]. These
E6 and E7 eVects on key apoptotic proteins such as Rb and
p53 have been demonstrated in HPV 16 and other high-risk
subtypes in in vitro assays [24, 27, 28]. HPV 6 and 11 E6
and E7 proteins do not readily bind to or degrade the p53 or
Rb proteins [14,  31,  46]. This suggests that alternative
mechanisms of altered cellular growth and proliferation
may exist for the low-risk subtypes of HPV. Furthermore,
there are little data on HPV 6 and 11 life cycles, replication,
maintenance and viral production in respiratory cells. It is




Surgical debulking is currently the treatment of choice;
newer surgical approaches utilizing microdebriders are
replacing laser ablation. Surgical excision aims to secure an
adequate airway and improve and maintain an acceptable
quality of voice [49].
HPV is present in the normal macroscopically unaVected
mucosa and it is currently not possible to distinguish
infected cells with a normal appearance from uninfected
epithelia. Repeated recurrences are frequent, however,
repeated attempts to treat the papillomas may cause serious
complications [40]. Current practice in the treatment of
RRP was recently evaluated by a questionnaire in the UK
[44]. Various lasers such as CO2, KTP, and pulsed dye
were found to be the preferred method of surgical removal
of RRP in children [49]. Spontaneous ventilation (65.3%) is
the preferred method of anaesthesia.
The frequent recurrence of papillomas has resulted in the
use of diVerent adjuvant treatments alongside surgical
removal of macroscopically obvious in the attempt to
improve outcomes. In the future, advances in the under-
standing of the immune response to HPV may improve our
treatment modalities and prevention strategies.
Adjuvant treatment
Adjuvant treatments currently used include cidofovir,
indole-3-carbinol, ribavirin, mumps vaccine, and photody-
namic therapy. As with surgical management, viral persis-
tence occurs following treatment with these adjuvant
modalities. Intralesional cidofovir may help control papil-
loma regrowth and reduce disease severity in many chil-
dren with RRP [39]. In most cases, cidofovir would appear
to be less eYcacious in producing disease eradication.
There appears to be little evidence to support prolonged
treatment regimes (i.e. more than eight treatments) [35].
Subcutaneously injected cidofovir has been tested on carti-
lage in a rabbit model [39]. There was a positive dose-
response relationship which existed for gross skin changes;
however, there was no dose-response relationship for sever-
ity of change in the epithelium. Higher doses of cidofovir
than commonly are used in the treatment of RRP may be
safe, although the eVects of repeat application and long-
term complications are not yet known. In animals, cidofovir
is carcinogenic (mammary adenocarcinoma in rats), embry-
otoxic and teratogenic [48]. Care must be taken in humans
that the possibility of pregnancy is excluded when usage is
considered. In view of the severe nephrotoxicity shown
when intravenous cidofovir is administered to animals and
humans, caution would be advised for repeated intrale-
sional or subcutaneous applications for RRP treatment. The
less common complications of bone marrow toxicity, iritis
and uveitis may also arise and vigilance is required from
clinicians.
Controlled trials failed to provide suYcient evidence to
draw reliable conclusions about the eVectiveness of antivi-
ral agents as adjuvant therapy in the management of RRP.
Further research is required before any speciWc antiviral
adjuvant therapy can be recommended.
Factors leading to virus activation in RRP have not been
recognized, however, extra-oesophageal acid reXux disease
(EERD) has been suggested as a possible factor, initially by
Borkowski et al. [6], and then by a group from Harvard in
2005 [29]. There is clinical evidence suggesting a link
between the presence of EERD and RRP. InXammation
induced by acid exposure may result in the expression of
HPV in susceptible tissues. Therefore, treatment of EERD
should be considered in all patients with diYcult to control
RRP with EERD.
Despite currently available surgical and adjuvant man-
agement options, tracheotomy may become necessary in
selected patients with extensive disease. Decannulation
should be performed as early as possible to avoid further
spread of viral infection and improve the quality of life.
The primary cause of papilloma extension to the lower air-
ways appears to be iatrogenic, i.e. the tracheotomies per-
formed in children with laryngeal papillomatosis (92.5% of150 Eur Arch Otorhinolaryngol (2008) 265:147–151
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cases). This was reported in a case group of 448 children
with RRP treated in St. Vladimir Moscow Children’s Hos-
pital between 1988 and 2003 [38].
The recent licensing of prophylactic HPV vaccines is a
most interesting development. In particular, the quadriva-
lent vaccine from Merck & SanoW-Pasteur (Gardasil®)
which shows eYcacy against HPV 6, 11, 16, 18 subtypes,
may be anticipated to impact upon the incidence of RRP.
The low incidence of RRP does pose signiWcant problems
in recruitment of suYcient numbers to show statistical sig-
niWcance. Large multi-centre collaborative clinical trials are
therefore required. Even so, suYcient clinical follow-up
data would take several years.
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